Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004)
Advanced Hepatocellular Carcinoma
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 2
- Patients
- 116 (final count)
- Started
- Mar 16, 2021
- Main results expected
- Jul 29, 2025
- Fully finished
- Jul 29, 2025
- Results posted
- Jun 23, 2026
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of Participants With a Dose-Limiting Toxicity (DLT) in the Safety Lead-in Phase
Measured over: 3 weeks
Number of Participants With ≥1 Adverse Event (AE)
Measured over: Up to approximately 44 months
Number of Participants With ≥1 Serious Adverse Event (SAE)
Measured over: Up to approximately 44 months
Number of Participants With ≥1 Immune-related AE (irAE)
Measured over: Up to approximately 44 months
Number of Participants With ≥1 Hepatic AE
Measured over: Up to approximately 44 months
Number of Participants Discontinuing Study Treatment Due to an AE
Measured over: Up to approximately 40 months
Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)
Measured over: Up to approximately 51 months
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT04740307 · record last updated 2026-06-30 · checked 2026-11-09 15:47 UTC